Insulet Reports Improved EVOLUTION 2C Trial Outcomes
Insulet Corporation on March 11 reported encouraging EVOLUTION 2C feasibility results for its fully closed-loop Omnipod insulin delivery system, showing time-in-range reached 68% (a 24% gain versus injection therapy) with only 0.14% time below range and no severe hypoglycemia or DKA. On March 13 Insulet disclosed a voluntary device correction for certain Omnipod 5 lots related to 18 serious adverse events; the company maintained guidance and Truist kept a Buy rating.
Scoring Rationale
Fresh same-day reporting of clinical trial results and an official device correction give moderate impact. Credibility is high due to conference presentation and company confirmation, but scope is limited to a small feasibility trial and has low relevance to core data-science topics, keeping the score moderate.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read OriginalTruist Maintains Insulet Corporation (PODD) Buy Rating Despite Device Correction Announcementinsidermonkey.com
